MktsMarkets

Estrella Immunopharma, Inc.
NASDAQ: ESLAKey statistics
ESLA News
Stories mentioning ESLA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q3 '24Sep 30 | Q2 '24Jun 30 | Q1 '24Mar 31 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,400 | 26.00 | 4,153 | 4,660 | 1,410 | 2,826 | 3,525 | 25.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,292 | 614.00 | 4,801 | 5,544 | 2,104 | 3,377 | 3,949 | 470.00 |
| Operating Income (Loss) | (2,292) | (614.00) | (4,801) | (5,544) | (2,104) | (3,377) | (3,949) | (470.00) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (2,292) | (614.00) | (4,801) | (5,544) | (2,104) | (3,377) | (3,949) | (470.00) |
| Tax Provision | 1.00 | 0.00 | 2.00 | |||||
| Net Income (Loss) | (2,292) | (614.00) | (4,801) | (5,545) | (2,104) | (3,377) | (3,951) | (470.00) |
| Earnings Per Share (Basic) | (0.05) | (0.02) | (0.13) | (0.15) | (0.06) | (0.09) | (0.11) | (0.01) |
| Earnings Per Share (Diluted) | (0.05) | (0.02) | (0.13) | (0.15) | (0.06) | (0.09) | (0.11) | (0.01) |
| Weighted Average Shares Outstanding (Basic) | 42,121 | 36,821 | 37,096 | 36,166 | 36,188 | 36,208 | 36,377 | 35,519 |
| Weighted Average Shares Outstanding (Diluted) | 42,121 | 36,821 | 37,096 | 36,166 | 36,188 | 36,208 | 36,377 | 35,519 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ESLA
Estrella Immunopharma, Inc. (NASDAQ: ESLA) is a stock listed on the Nasdaq Stock Market under the ticker symbol ESLA. It last traded at $0.5100 (Nov 13, 2026, 4:00 PM ET), down 0.9% on the day. That gives Estrella Immunopharma a market capitalisation of $22.4M.
Over the past 52 weeks ESLA has traded between $0.2400 and $2.71.
For the quarter ended Mar 31, 2026 it reported a net loss of $2.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$2.3M |
| Dec 31, 2025 | — | -$614.0K |
| Sep 30, 2025 | — | -$4.8M |
| Jun 30, 2025 | — | -$5.5M |
From Estrella Immunopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…